Short answer
MIMEDX GROUP, INC. (MDXG) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.2 (Exhibit EX-99.2). MiMedx announced second-quarter 2026 results on October 28, 2026.
MIMEDX GROUP, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- MiMedx announced second-quarter 2026 results on October 28, 2026
- Detailed financial results and management commentary are provided in Exhibit 99.1, the earnings press release
Item 7.01 · Regulation FD Disclosure
- October 28, 2026 earnings call covering third-quarter 2026 financial and operating results
- Investor presentation updated October 28, 2026, offering supplemental operating and strategic information
- Exhibit 99.2 contains earnings-call slides, while Exhibit 99.3 contains updated investor materials
Item EX-99.1 · Exhibit EX-99.1
- Q3 net sales $62.3M, down 45%, driven by Wound sales falling 71% despite Surgical sales growth of 9%
- Adjusted EBITDA $2.1M, margin 3.3%, versus $35.0M and 30.7% prior year, showing severe earnings pressure
- GAAP net loss $8.7M versus $16.7M profit, while SG&A fell to $58.3M after cost reductions
- Cash $120.8M, with the remaining $17M term loan repaid and no debt outstanding
- 2026 sales outlook reduced to $250M-$260M, while Sanara acquisition remains subject to FTC HSR clearance
Item EX-99.2 · Exhibit EX-99.2
- Q3 net sales $62MM, with Surgical $40MM and Wound $22MM
- Surgical volume growth reached mid-teens, while Wound Care Center volumes rose 7% sequentially and over 20% year-over-year
- Adjusted EBITDA $2.1MM, margin 3.3%, versus $35.0MM and 30.7% in Q3 2025
- AXIOFILL FDA classifications vacated and remanded, preserving regulatory pathway and commercial opportunity
- Sanara deal faces additional FTC review, backed by committed $300MM term financing at Term SOFR plus 6.25%
- 2026 net sales outlook $250–260MM, with Q4 Adjusted EBITDA expected to increase sequentially
Item EX-99.3 · Exhibit EX-99.3
- Proposed Sanara acquisition values target at approximately $350 million, funded partly by a $300 million term loan and 4.4 million MDXG shares
- Debt terms: six-year maturity at SOFR plus 6.25%, creating meaningful post-close interest and leverage exposure
- Expected first-year combined revenue near $400 million, over $20 million annualized cost synergies in 2027, and adjusted EBITDA margin above 20%
- FTC clearance remains the final major closing hurdle, leaving timing and completion risk unresolved
- Q3 2026 net sales $62 million, adjusted EBITDA $2.1 million versus $35.0 million, with margin declining to 3.3% from 30.7%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MIMEDX GROUP, INC. 8-K filings
Get the next MDXG 8-K as it lands
Follow MDXG for push alerts, or ask the research agent what this filing means.